Subarachnoid hemorrhage: management considerations for COVID-19
Eric J. Panther , Brandon Lucke-Wold
Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (2) : 65 -73.
Subarachnoid hemorrhage (SAH) has deleterious outcomes for patients, and during the hospital stay, patients are susceptible to vasospasm and delayed cerebral ischemia. Coronavirus disease 2019 (COVID-19) has been shown to worsen hypertension through angiotensin-converting enzyme 2 (ACE2) activity, therefore, predisposing to aneurysm rupture. The classic renin-angiotensin pathway activation also predisposes to vasospasm and subsequent delayed cerebral ischemia. Matrix metalloproteinase 9 upregulation can lead to an inflammatory surge, which worsens outcomes for patients. SAH patients with COVID-19 are more susceptible to ventilator-associated pneumonia, reversible cerebral vasoconstriction syndrome, and respiratory distress. Emerging treatments are warranted to target key components of the anti-inflammatory cascade. The aim of this review is to explore how the COVID-19 virus and the intensive care unit (ICU) treatment of severe COVID can contribute to SAH.
Subarachnoid hemorrhage / COVID-19 / renin-angiotensin pathway / matrix metalloproteinase 9 / outcomes
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014; 10: 44-58. |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Tang H, Wang Q, Xu F, Zhang X, Zeng Z, Yan Y, |
| [15] |
|
| [16] |
Akpek M. Does COVID-19 cause hypertension? Angiology. 2021;[Epub ahead of print]. |
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
Scheer M, Harder A, Wagner S, Ibe R, Prell J, Scheller C, |
| [38] |
|
| [39] |
Moreno G, Carbonell R, Martin-Loeches I, Solé-Violán J, Correig I Fraga E, Gómez J, et al; COVID-19 SEMICYUC Working Group. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Ann Intensive Care. 2021; 11: 159. |
| [40] |
|
| [41] |
|
| [42] |
Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, |
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
/
| 〈 |
|
〉 |